A photodynamic therapy patient survey: real-life experience from two regional services

Bernard  Ho; Natasha  Howard; Sandra  Howard; Andrea Cochrane; John  Ferguson; Sally Ibbotson

doi:10.1111/phpp.12638

A photodynamic therapy patient survey: real-life experience from two regional services

Bernard Ho (Lead / Corresponding author), Natasha Howard, Sandra Howard, Andrea Cochrane, John Ferguson, Sally Ibbotson

Undergraduate Medicine

Research output: Contribution to journal › Letter › peer-review

148 Downloads (Pure)

Abstract

Topical photodynamic therapy (PDT) is widely used for actinic keratoses (AK), Bowen’s disease (BD) and superficial basal cell carcinoma (BCC), with a strong evidence‐base regarding efficacy and high levels of patient satisfaction. The British Association of Dermatologists published standards for PDT service delivery to ensure appropriate clinical governance, training and practices. Topical PDT involves application of a photosensitiser pro‐drug (5‐aminolaevulinic acid or methylaminolevulinate) and subsequent visible light exposure, generally using red LED light (conventional PDT; cPDT). This initiates PDT phototoxicity, usually resulting in discomfort, pain and inflammation. Daylight PDT (dPDT) is also increasingly used for AK with high levels of tolerance.

Original language	English
Pages (from-to)	226-229
Number of pages	4
Journal	Photodermatology, Photoimmunology & Photomedicine
Volume	37
Issue number	3
Early online date	10 Dec 2020
DOIs	https://doi.org/10.1111/phpp.12638
Publication status	Published - May 2021

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Radiology Nuclear Medicine and imaging
Dermatology

Access to Document

10.1111/phpp.12638

Author Accepted ManuscriptAccepted author manuscript, 443 KB

Cite this

@article{fbc2d7874e784be28446355d3fe7fa60,

title = "A photodynamic therapy patient survey: real-life experience from two regional services",

abstract = "Topical photodynamic therapy (PDT) is widely used for actinic keratoses (AK), Bowen{\textquoteright}s disease (BD) and superficial basal cell carcinoma (BCC), with a strong evidence‐base regarding efficacy and high levels of patient satisfaction. The British Association of Dermatologists published standards for PDT service delivery to ensure appropriate clinical governance, training and practices. Topical PDT involves application of a photosensitiser pro‐drug (5‐aminolaevulinic acid or methylaminolevulinate) and subsequent visible light exposure, generally using red LED light (conventional PDT; cPDT). This initiates PDT phototoxicity, usually resulting in discomfort, pain and inflammation. Daylight PDT (dPDT) is also increasingly used for AK with high levels of tolerance.",

author = "Bernard Ho and Natasha Howard and Sandra Howard and Andrea Cochrane and John Ferguson and Sally Ibbotson",

year = "2021",

month = may,

doi = "10.1111/phpp.12638",

language = "English",

volume = "37",

pages = "226--229",

journal = "Photodermatology, Photoimmunology & Photomedicine",

issn = "0905-4383",

publisher = "Wiley",

number = "3",

}

TY - JOUR

T1 - A photodynamic therapy patient survey

T2 - real-life experience from two regional services

AU - Ho, Bernard

AU - Howard, Natasha

AU - Howard, Sandra

AU - Cochrane, Andrea

AU - Ferguson, John

AU - Ibbotson, Sally

PY - 2021/5

Y1 - 2021/5

N2 - Topical photodynamic therapy (PDT) is widely used for actinic keratoses (AK), Bowen’s disease (BD) and superficial basal cell carcinoma (BCC), with a strong evidence‐base regarding efficacy and high levels of patient satisfaction. The British Association of Dermatologists published standards for PDT service delivery to ensure appropriate clinical governance, training and practices. Topical PDT involves application of a photosensitiser pro‐drug (5‐aminolaevulinic acid or methylaminolevulinate) and subsequent visible light exposure, generally using red LED light (conventional PDT; cPDT). This initiates PDT phototoxicity, usually resulting in discomfort, pain and inflammation. Daylight PDT (dPDT) is also increasingly used for AK with high levels of tolerance.

AB - Topical photodynamic therapy (PDT) is widely used for actinic keratoses (AK), Bowen’s disease (BD) and superficial basal cell carcinoma (BCC), with a strong evidence‐base regarding efficacy and high levels of patient satisfaction. The British Association of Dermatologists published standards for PDT service delivery to ensure appropriate clinical governance, training and practices. Topical PDT involves application of a photosensitiser pro‐drug (5‐aminolaevulinic acid or methylaminolevulinate) and subsequent visible light exposure, generally using red LED light (conventional PDT; cPDT). This initiates PDT phototoxicity, usually resulting in discomfort, pain and inflammation. Daylight PDT (dPDT) is also increasingly used for AK with high levels of tolerance.

UR - http://www.scopus.com/inward/record.url?scp=85098071414&partnerID=8YFLogxK

U2 - 10.1111/phpp.12638

DO - 10.1111/phpp.12638

M3 - Letter

C2 - 33301621

SN - 0905-4383

VL - 37

SP - 226

EP - 229

JO - Photodermatology, Photoimmunology & Photomedicine

JF - Photodermatology, Photoimmunology & Photomedicine

IS - 3

ER -

A photodynamic therapy patient survey: real-life experience from two regional services

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this